Eli Lilly's diabetes medication Mounjaro generated $10 billion in quarterly revenue, reflecting a 65% year-over-year increase

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.